<DOC>
	<DOCNO>NCT01099514</DOCNO>
	<brief_summary>Major response observe imatinib mesylate KIT-mutated metastatic rectal melanoma ( Hodi FS et al , J Clin Oncol 26:2046-2051 , 2008 ) . In ASCO annual meeting 2009ar , KIT mutation report present 23 % acral 15.2 % mucosal melanoma ( Heinrich MC et al , J Clin Oncol 26:2008 abstr 9016 ) . Nilotinib novel tyrosine kinase inhibitor ( TKI ) target KIT , PDGFR , Bcr-Abl inhibit proliferate imatinib-sensitive imatinib-resistant cell vitro . Phase I study nilotinib alone combination imatinib patient imatinib-resistant gastrointestinal stromal tumor ( GIST ) demonstrate significant activity ( 72 % stable disease nilotinib alone 56 % nilotinib/imatinib combination ) ( Blay JY et al , J Clin Oncol 26:2008 , abstr 10553 ) . Thus , propose conduct phase II study nilotinib metastatic melanoma KIT mutation .</brief_summary>
	<brief_title>Study Nilotinib Metastatic Melanoma With KIT Aberrations</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Histologically cytologically proven melanoma stage IV unresectable stage III disease 2 . Documented KIT aberration 3 . Adequate organ function define follow criterion : Serum aspartate transaminase ( AST ) ; serum glutamic oxaloacetic transaminase ( SGOT ) ) serum alanine transaminase ( ALT ) ; serum glutamic pyruvic transaminase ( SGPT ) ) ≤ 2.5 x local laboratory upper limit normal ( ULN ) , AST ALT less equal 5 x ULN liver function abnormality due underlie malignancy Total serum bilirubin ≤ 1.5 x ULN Absolute neutrophil count ( ANC ) ≥ 1500/µL Platelets ≥ 100,000/µL Hemoglobin ≥ 9.0 g/dL ( may transfuse erythropoietin treat ) Serum calcium ≤ 12.0 mg/dL Serum creatinine ≤ 1.5 x ULN 4 . Patients CNS metastasis must stable neurologic function without evidence CNS progression within 8 week 5 . May previous adjuvant therapy interferon , vaccine therapy IL2 , chemotherapy 6 . At least one measurable lesion RECIST criterion 7 . ECOG PS 02 1 . Major surgery radiation therapy within 4 week start study treatment . 2 . History know carcinomatous meningitis , evidence symptomatic leptomeningeal disease screen CT MRI scan . 3 . Ongoing cardiac dysrhythmias NCI CTCAE grade ≥ 2 . 4 . QTc &gt; 470 msec baseline EKG . 5 . Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>